STAT

Congress isn’t acting to curb drug prices, so states are stepping up. Here’s how

With little action in Congress, states from California to Vermont are experimenting with ways to try to curb drug prices or shine a light on rising costs.

President Trump has complained that drug makers are getting away with murder — and he may be right.

Despite vociferous complaints from consumers that drug prices are too high, Congress has failed to act. And with few exceptions, the pharmaceutical industry has successfully delayed or thwarted state bills that would force drug makers to explain or justify price hikes.

But that may be starting to change. Last week, of the pharma industry, already has a similar policy in place.  recently began requiring drug makers to disclose pricing data about diabetes medicines. And has a new law that penalizes generic companies for price gouging.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: No, Alcohol Isn’t Good For You. Will New Dietary Guidelines Be Shaped More By Health Or Industry Interests?
More and more studies show that alcohol isn't healthy after all. Dietary guidelines are up for revision in 2025, and already, there's debate over research and industry influence.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT1 min read
STAT+: Health Care Leaders Plot How To Expand Diversity In Clinical Trials
Experts gathered at the Milken Institute Global Conference this week to discussed potential strategies to expand diversity in clinical trials. Here are some of their big ideas.

Related Books & Audiobooks